Last reviewed · How we verify

Incidence of acute kidney injury

Hospices Civils de Lyon · Phase 2 active Biologic

Incidence of acute kidney injury is a Biologic drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development.

At a glance

Generic nameIncidence of acute kidney injury
SponsorHospices Civils de Lyon
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Incidence of acute kidney injury

What is Incidence of acute kidney injury?

Incidence of acute kidney injury is a Biologic drug developed by Hospices Civils de Lyon.

Who makes Incidence of acute kidney injury?

Incidence of acute kidney injury is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What development phase is Incidence of acute kidney injury in?

Incidence of acute kidney injury is in Phase 2.

Related